Swiss Re’s Bristol-Myers Squibb BMY Stock Holding History

Swiss Re’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$117K	Buy	2,029 +1,559	+332%	+$89.5K	0.01%	209
2026 Q1	$28.5K	Hold	470	–	–	0.17%	81
2025 Q4	$25.4K	Buy	+470	New	+$22.6K	﹤0.01%	96

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swiss Re's BMY Position: Q2 2026 in Review

Swiss Re increased its Bristol-Myers Squibb (BMY) stake by 332% in Q2 2026, buying an estimated $89.5K and bringing the position to 2,029 shares worth $117K. The position accounts for 0.01% of the portfolio, ranked #209.

Swiss Re first reported a position in BMY in Q4 2025 and has held it in 3 quarters since. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Swiss Re held 2,029 shares of Bristol-Myers Squibb worth $117K as of Q2 2026.
Swiss Re bought 1,559 Bristol-Myers Squibb shares in Q2 2026, an estimated $89.5K.
Bristol-Myers Squibb made up 0.01% of Swiss Re's portfolio in Q2 2026, its #209 holding.
Swiss Re first reported a position in Bristol-Myers Squibb in Q4 2025 and has held it in 3 quarters since.
2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Swiss Re's 13F filing for Q2 2026, filed 11 Aug 2026.